Industry Dialogue on PRIP Strengthens Pharma Ecosystem

17 Mar 2025 CW Team

Government Initiatives to Boost Innovation In addition to the PRIP Scheme, the dialogue highlighted key government initiatives aimed at promoting research and innovation in the sector:

ICMR’s PATENT MITRA, MEDTECH MITRA, and INTENT programs – Supporting patent filing, guiding the innovation journey, and facilitating clinical trials. CSIR’s Innovation Complex in Mumbai – Bridging the gap between research institutions and industry through translational research. Industry Leaders Call for Stronger Policy and Investment Support Prominent industry figures voiced their insights on the challenges and opportunities in Pharma-MedTech R&D:

Dr Sharvil Patel, Vice President, Indian Pharmaceutical Association (IPA) – Stressed the importance of industry-driven innovation, regulatory support, and increased investments in emerging pharmaceutical technologies. Mr Anil Matai, Director General, Organisation of Pharmaceutical Producers of India (OPPI) – Highlighted the need for a conducive policy environment to encourage greater industry participation in R&D. Mr Bharat Shah, National President, Indian Drug Manufacturers' Association (IDMA) – Addressed the challenges MSMEs face in adopting research-led growth strategies and welcomed the PRIP scheme’s role in catalysing innovation. Mr Veeraal Gandhi, Vice President, Association of Diagnostics Manufacturers India (ADMI) – Spoke on India’s potential to lead in diagnostic technologies, particularly in point-of-care innovations, to enhance advanced healthcare solutions. Government’s Vision for Future-Ready Healthcare Solutions Shri Amit Agrawal, Secretary, Department of Pharmaceuticals, underscored the importance of futuristic products and affordable healthcare solutions as key drivers of India’s global leadership in pharmaceuticals and MedTech. He emphasised that:

Data-driven markets will play a transformative role in shaping Pharma-MedTech R&D. India, with its highly diverse gene pool and one-sixth of the world’s population, has a unique advantage in developing personalised and precision medicines. The PRIP Scheme aims to support innovative, cost-effective, and affordable healthcare solutions that will strengthen domestic and global healthcare ecosystems. Breakout Sessions and Stakeholder Engagement The event featured breakout sessions, where industry representatives and stakeholders provided insights on emerging R&D trends, regulatory pathways, and funding opportunities. Discussions covered:

Enhancing industry-academia collaboration to drive research and innovation. Streamlining regulatory pathways to facilitate faster commercialisation of new technologies. Scaling up research initiatives to fuel sectoral growth. Stakeholders were encouraged to submit their feedback and project details via the Expression of Interest (EoI) on the Department of Pharmaceuticals website, open until April 7, 2025. This process aims to refine the PRIP Scheme’s implementation to better align with industry needs.

The Industry Dialogue in Mumbai concluded on a highly optimistic note, with participants reaffirming their commitment to fostering an innovation-driven ecosystem in the Pharma-MedTech sector. The event reinforced government-industry collaboration, paving the way for transformative advancements in healthcare, pharmaceuticals, and medical technology.

The Department of Pharmaceuticals, Government of India, convened an Industry Dialogue in Mumbai to discuss the Promotion of Research and Innovation in the Pharma-MedTech Sector (PRIP) Scheme. The event brought together industry leaders, research institutions, and pharmaceutical associations, including representatives from the Indian Council for Medical Research (ICMR), the Council of Scientific and Industrial Research (CSIR), and the National Institute of Pharmaceutical Education and Research (NIPERs). Discussions focused on strengthening industry-academia linkages, fostering collaboration, and leveraging government initiatives to accelerate R&D and commercialise innovative solutions in the pharmaceutical and medical technology sectors. Government Initiatives to Boost Innovation In addition to the PRIP Scheme, the dialogue highlighted key government initiatives aimed at promoting research and innovation in the sector: ICMR’s PATENT MITRA, MEDTECH MITRA, and INTENT programs – Supporting patent filing, guiding the innovation journey, and facilitating clinical trials. CSIR’s Innovation Complex in Mumbai – Bridging the gap between research institutions and industry through translational research. Industry Leaders Call for Stronger Policy and Investment Support Prominent industry figures voiced their insights on the challenges and opportunities in Pharma-MedTech R&D: Dr Sharvil Patel, Vice President, Indian Pharmaceutical Association (IPA) – Stressed the importance of industry-driven innovation, regulatory support, and increased investments in emerging pharmaceutical technologies. Mr Anil Matai, Director General, Organisation of Pharmaceutical Producers of India (OPPI) – Highlighted the need for a conducive policy environment to encourage greater industry participation in R&D. Mr Bharat Shah, National President, Indian Drug Manufacturers' Association (IDMA) – Addressed the challenges MSMEs face in adopting research-led growth strategies and welcomed the PRIP scheme’s role in catalysing innovation. Mr Veeraal Gandhi, Vice President, Association of Diagnostics Manufacturers India (ADMI) – Spoke on India’s potential to lead in diagnostic technologies, particularly in point-of-care innovations, to enhance advanced healthcare solutions. Government’s Vision for Future-Ready Healthcare Solutions Shri Amit Agrawal, Secretary, Department of Pharmaceuticals, underscored the importance of futuristic products and affordable healthcare solutions as key drivers of India’s global leadership in pharmaceuticals and MedTech. He emphasised that: Data-driven markets will play a transformative role in shaping Pharma-MedTech R&D. India, with its highly diverse gene pool and one-sixth of the world’s population, has a unique advantage in developing personalised and precision medicines. The PRIP Scheme aims to support innovative, cost-effective, and affordable healthcare solutions that will strengthen domestic and global healthcare ecosystems. Breakout Sessions and Stakeholder Engagement The event featured breakout sessions, where industry representatives and stakeholders provided insights on emerging R&D trends, regulatory pathways, and funding opportunities. Discussions covered: Enhancing industry-academia collaboration to drive research and innovation. Streamlining regulatory pathways to facilitate faster commercialisation of new technologies. Scaling up research initiatives to fuel sectoral growth. Stakeholders were encouraged to submit their feedback and project details via the Expression of Interest (EoI) on the Department of Pharmaceuticals website, open until April 7, 2025. This process aims to refine the PRIP Scheme’s implementation to better align with industry needs. The Industry Dialogue in Mumbai concluded on a highly optimistic note, with participants reaffirming their commitment to fostering an innovation-driven ecosystem in the Pharma-MedTech sector. The event reinforced government-industry collaboration, paving the way for transformative advancements in healthcare, pharmaceuticals, and medical technology.

Resources

03 Jun 2026

Jyoti Structures Launches Heat Safety Drive Across Sites

Jyoti Structures (JSL) has strengthened heat safety measures across its project sites and manufacturing facilities as temperatures rise across India. The company has implemented a Summer Safety Plan covering all transmission line projects to address risks related to heat stress, dehydration and worker fatigue.The initiative includes rescheduling work away from peak afternoon temperatures, provision of drinking water, ORS and lemon-salt solutions, and installation of rest shelters near work areas. Daily toolbox talks, worker health monitoring, first-aid preparedness, emergency transport arrange..

Real Estate

03 Jun 2026

MHADA Declares 82 Buildings Most Dangerous in Central and South Mumbai

The Maharashtra Housing and Area Development Authority (MHADA) has declared 82 buildings as most dangerous across Central and South Mumbai and has appealed to residents to vacate immediately. The list, prepared after structural assessments by the authority, identifies buildings judged to pose imminent risk to occupants and to passersby. Local civic bodies have been asked to coordinate evacuations and to make arrangements for temporary shelter and rehabilitation for displaced households. Officials said the authority prioritised buildings with visible structural distress, severe cracking, tiltin..

Infrastructure Transport

03 Jun 2026

Damage Reported At Halwara Airport Terminal After First Rains

Severe damage was reported at the terminal of Halwara Airport during the first major rain spell of the season, prompting immediate concern among aviation and local authorities. Images from the site showed water ingress and visible deterioration of the terminal interior, affecting passenger areas and ancillary services. The airport authority suspended certain operations temporarily to assess structural safety and ensure passenger wellbeing. Preliminary inspections have prioritised electrical systems and roof seals to prevent further water ingress. State aviation officials ordered a formal inqui..